1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cannabinoid Receptor Type 2 (CB2) Agonists -Pipeline Insights, 2016


DelveInsight’s, “Cannabinoid Receptor Type 2 (CB2) Agonists-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Cannabinoid Receptor Type 2 (CB2) Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Cannabinoid Receptor Type 2 (CB2) Agonists. DelveInsight’s Report also assesses the Cannabinoid Receptor Type 2 (CB2) Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Cannabinoid Receptor Type 2 (CB2) Agonists
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Cannabinoid Receptor Type 2 (CB2) Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Cannabinoid Receptor Type 2 (CB2) Agonists and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Cannabinoid Receptor Type 2 (CB2) Agonists -Pipeline Insights, 2016

- Cannabinoid Receptor Type 2 (CB2) Agonists Overview
- Cannabinoid Receptor Type 2 (CB2) Agonists Disease Associated
- Cannabinoid Receptor Type 2 (CB2) Agonists Pipeline Therapeutics
- Cannabinoid Receptor Type 2 (CB2) Agonists Therapeutics under Development by Companies
- Cannabinoid Receptor Type 2 (CB2) Agonists Filed and Phase III Products
- Comparative Analysis
- Cannabinoid Receptor Type 2 (CB2) Agonists Phase II Products
- Comparative Analysis
- Cannabinoid Receptor Type 2 (CB2) Agonists Phase I and IND Filed Products
- Comparative Analysis
- Cannabinoid Receptor Type 2 (CB2) Agonists Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Cannabinoid Receptor Type 2 (CB2) Agonists - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cannabinoid Receptor Type 2 (CB2) Agonists - Discontinued Products
- Cannabinoid Receptor Type 2 (CB2) Agonists - Dormant Products
- Companies Involved in Therapeutics Development for Cannabinoid Receptor Type 2 (CB2) Agonists
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Cannabinoid Receptor Type 2 (CB2) Agonists by Therapy Area, 2016
- Number of Products under Development for Cannabinoid Receptor Type 2 (CB2) Agonists, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Monotherapy Products
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Combination Products
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Route of Administration
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Stage and Route of Administration
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Molecule Type
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Stage and Molecule Type
- Cannabinoid Receptor Type 2 (CB2) Agonists Therapeutics - Discontinued Products
- Cannabinoid Receptor Type 2 (CB2) Agonists Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Cannabinoid Receptor Type 2 (CB2) Agonists by Therapy Area, 2016
- Number of Products under Development for Cannabinoid Receptor Type 2 (CB2) Agonists, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Monotherapy Products
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Combination Products
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Route of Administration
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Stage and Route of Administration
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Molecule Type
- Cannabinoid Receptor Type 2 (CB2) Agonists Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Global Radiofrequency Ablation Devices for Pain Management Market: Scope and Methodology This report on radiofrequency ablation devices for pain management market studies the current as well as future ...

Cold Pain Therapy Market by Product, Application - Forecast to 2021

Cold Pain Therapy Market by Product, Application - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global cold pain therapy market is estimated to grow at a CAGR of 5.0% from 2016 to 2021 to reach USD 1,087.7 million by 2021. The adoption of cold pain therapy products is rising across the globe ...

Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

Pain Management Drugs and Devices - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Pain Management Drugs and Devices market is expected to grow from $39.48 billion in 2015 to reach $58.2 billion by 2022 with a CAGR of 5.7%. Growing various pain ...


Download Unlimited Documents from Trusted Public Sources

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Anti-Infective Market in Ghana

  • December 2016
    10 pages
  • Anti-Infective  

  • Ghana  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Related Market Segments :

Analgesic

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.